Relmada Therapeutics, Inc.
-
Ticker
RLMD
-
Industry
Drug Manufacturers - Other More
-
Sector
Healthcare More
- 1-10 Employees
- Based in New York City, New York
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists
…More may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
REPORT RATINGS
4.8 / 5.0 (126)
Relmada Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 126 reviews.
Relmada Therapeutics, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports